Pfizer follows CR pregabalin epilepsy failure with success in Phase III fibromyalgia trial
This article was originally published in Scrip
Executive Summary
Pfizer has fared better in the second out of three Phase III trials of its controlled-release (CR) formulation of the GABA analogue, pregabalin, this time in the indication of fibromyalgia.